Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Palo Alto Networks Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.44 (market cap $5.07B), while Palo Alto Networks Inc trades at $382.76 (market cap $312.80B). The key difference: Palo Alto Networks Inc is far larger — about 61.7× ACADIA Pharmaceuticals Inc.'s market cap. Which is the better fit depends on your goals.
| ACAD | PANW | |
|---|---|---|
Market Cap | $5.07B | $312.80B |
Sector | Health | Technology |
52-Week High | $29.41 | $385.04 |
52-Week Low | $20.06 | $141.67 |
Enterprise Value | $4.19B | $311.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Palo Alto Networks (PANW) trades at $385.04, up 5.82% over the past day, reflecting strong momentum amid positive sentiment around AI-driven cybersecurity demand. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, while RSI levels suggest potential overbought conditions. Fundamentally, the company reported revenue of $9.22B in 2025 with a net income margin of 7.95%, though valuation ratios like P/E of 333.74 indicate a premium. Recent news highlights record highs following the Black Hat conference and AI platform launches, though a Chinese regulatory review introduces near-term uncertainty.
The outlook for PANW remains positive given robust revenue growth, AI integration, and Wall Street's bullish consensus, but risks include elevated valuation, integration costs from acquisitions, and geopolitical scrutiny. Investors should weigh the company's leadership in cybersecurity against potential volatility from regulatory developments and high expectations priced into the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
